Similarly, antibody-drug conjugates such as ado-trastuzumab emtansine and fam-trastuzumab deruxtecan have been approved by the United States Food and Drug Association for treatment of HER2+ metastatic disease, and CNS activity has been reported21,42. The gene discussed is ERBB2; the disease is metastatic neoplasm.